Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Spyre Therapeutics, Inc. - Common Stock
(NQ:
SYRE
)
33.24
+0.15 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Spyre Therapeutics, Inc. - Common Stock
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
January 12, 2026
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics' CEO Sells 15,000 Shares
↗
January 11, 2026
This biotech innovator in antibody therapies for inflammatory bowel disease reported a notable insider sale, according to a recent SEC filing.
Via
The Motley Fool
Topics
Regulatory Compliance
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 04, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
November 04, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
October 29, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
October 24, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
October 15, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
↗
October 14, 2025
Via
Benzinga
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
October 13, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 10, 2025
Via
Benzinga
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
October 05, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
September 26, 2025
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...
Via
Benzinga
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
September 15, 2025
From
Spyre Therapeutics, Inc.
Via
GlobeNewswire
Spyre (SYRE) Q2 R&D Up 23% Loss Narrows
↗
August 06, 2025
Via
The Motley Fool
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
↗
April 08, 2025
Via
Benzinga
SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
December 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024
↗
August 07, 2024
SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024
↗
May 09, 2024
SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
↗
March 05, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Via
Benzinga
Topics
Stocks
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
